Amicus Therapeutics Stock Statistic Functions Linear Regression Intercept
| FOLD Stock | USD 14.38 0.01 0.07% |
| Symbol |
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Linear Regression Intercept is the expected mean value of Amicus Therapeutics price seriese where values of its benchmark or peer price series are zero.
Amicus Therapeutics Technical Analysis Modules
Most technical analysis of Amicus Therapeutics help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Amicus from various momentum indicators to cycle indicators. When you analyze Amicus charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Amicus Therapeutics Inc
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania. Amicus Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 496 people. This overview emphasizes how Amicus Therapeutics compares to peers on valuation quality and operating consistency. Current metrics include P/B of 16.44, profit margin of -4.28%. Amicus Therapeutics has a market cap of 4.51 B, ROE of -11.58%. 
Gabriel Shpitalnik ยท Member of Macroaxis Editorial Board
Methodology
Unless otherwise specified, financial data for Amicus Therapeutics is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Amicus (USA Stocks:FOLD) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: The dataset for Amicus Therapeutics incorporates public filings and market reference sources and official institutional disclosures, including U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Some inputs may not update instantaneously. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Amicus Therapeutics may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Amicus Stock is Curated By:
Gabriel Shpitalnik ยท Member of Macroaxis Editorial BoardAlign your values with your investing style
Using Amicus Therapeutics inside a theme workflow gives investors a structured way to compare related stocks, funds, ETFs, and crypto assets before allocating capital. The practical benefit is that the selected idea can be tuned either for higher upside or for tighter risk control.
Thematic Opportunities
Explore Investment Opportunities
Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Momentum Invested over 20 shares | |
 | Driverless Cars Invested over 40 shares | |
 | Hedge Favorites Invested over 200 shares | |
 | Blockchain Invested few shares | |
 | Macroaxis Index Invested over 60 shares | |
 | Marketing Invested few shares | |
 | Baby Boomer Prospects Invested over 20 shares | |
 | Impulse Invested over 200 shares | |
 | Cash Cows Invested few shares | |
 | Artificial Intelligence Invested few shares | |
More Resources for Amicus Stock Analysis
A comprehensive view of Amicus Therapeutics starts with financial statements and ratio context. Key ratios help frame profitability, efficiency, and growth context for Amicus Therapeutics Stock. Key reports that frame Amicus Therapeutics Stock are listed below:Amicus Therapeutics has a market cap of 4.51 B, operating margin of 8.61%, ROE of -11.58%. Review Investing Opportunities for broader portfolio context. This reflects a position in Amicus Therapeutics in the portfolio view. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. Our How to Invest in Amicus Therapeutics guide provides practical guidance on trading Amicus Stock.Analysis related to Amicus Therapeutics should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Quarterly Earnings Growth -0.95 | Earnings Share -0.09 | Revenue Per Share | Quarterly Revenue Growth 0.237 | Return On Assets |
Amicus Therapeutics market price can diverge from book value, the accounting figure shown on Amicus balance sheet. Amicus Therapeutics' market capitalization is 4.51 B. With a P/B ratio of 16.44, the market values Amicus Therapeutics well above its book equity. Enterprise value stands at 4.66 B. Intrinsic value is an analytical estimate of Amicus Therapeutics' underlying worth that can differ from price and book value. Valuation methods help interpret those gaps.
It is useful to distinguish Amicus Therapeutics' value from its trading price, which are computed with different methods. For Amicus Therapeutics, key inputs include a P/B ratio of 16.44, a profit margin of -4.28%, ROE of -11.58%, and revenue of 634.21 M. By contrast, market price reflects the level where buyers and sellers transact.